Performance Indicators

 

Performance Indicators Commentary

The 2017 performance indicators for the five registries of the UKIACR are available here.

You can click on the various tabs to view the corresponding comparison tables. You can use the search box above the table to filter it, or click on any column in the table to sort by it (if applicable). Please read the notes under each table, as sometimes the data is not directly comparable.

A detailed commentary of the findings for each registry may be found at this link.

An Excel download of the complete results tables may be found at this link.

Old Performance Indicators Reports

Reports are also available for preceding years. Use the links below to access these reports:

Executive summary
Target not reached or not in line with other registries
Target attained
Indicator Country average (population) Country average (country) England Scotland Northern Ireland
Stability: Percentage change (%) for all cancers (C00-C97 ex. C44) in 2016 compared with 2013-2015 0.2% -0.4% 0.6% 4.1% 2.2%
Registry Creep: Percentage (%) for all cancers (C00-C97 ex. C44) of 2015 registrations at 31/01/2018 compared with registrations at 31/01/2017 1.3% 2.1% 1.1% 3.0% 2.1%
Staging: Proportion (%) of all cases (C00-C97 ex. C44) with valid known stage registered out of all 2016 registered cancers (C00-C97 ex. C44) 80.6% 77.9% 81.9% 67.2% 84.7%
Average of Core Patient Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with demographic information 98.5% 94.3% 99.1% 96.3% 87.5%
Average of Core Tumour Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with tumour information 97.3% 96.2% 97.4% 96.5% 94.6%
Diagnosing Hospital Known: Percentage (%) of all cancers (C00-C97 ex. C44) registered with an organisation of diagnosis 97.2% 91.7% 98.0% 93.5% 83.6%
Death Certificate Only (DCO) Rates: Percentage (%) of all cancers (C00-C97 ex. C44) registered as a DCO 0.5% 0.4% 0.5% 0.2% 0.4%
Zero Day Survivors: Percentage (%) of all cancers (C00-C97 ex. C44) registered with the date of death equals the date of diagnosis 1.2% 0.9% 1.3% 0.6% 0.7%
Microscopically Verified: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified 85.2% 84.8% 85.3% 83.9% 85.3%
Non Specific Codes: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified with non specific morphology codes 1.2% 1.3% 1.2% 1.2% 1.5%
Grade: Percentage (%) of all cancers (C00-C97 ex. C44) registered with a known grade 60.2% 61.1% 60.2% 58.6% 64.4%
Treatment: Percentage (%) of all cancers (C00-C97 ex. C44) registered with any treatment 87.1% 79.2% 88.9% 69.5% NA
Breast Screening Data: Percentage of breast cancer (C50) cases from 2015 screen detected for ages 50-64 45.1% 48.1% 44.3% 51.4% 48.4%
Cervical Screening Data: Percentage of cervical cancer (C53) cases from 2015 screen detected for ages 25-60 32.0% 37.7% 30.0% 45.3% NA
Bowel Screening Data: Percentage of bowel cancer (C18-C20) cases from 2015 screen detected for ages 60-69 24.9% 25.9% 24.6% 27.1% NA
  • Core Patient information includes name, address, postcode, sex, date of birth, ethnicity, date of death, unique health identifier
  • Core Tumour information includes date of diagnosis, site of primary growth, type of growth, behaviour of growth, basis of diagnosis, hospital of diagnosis
  • NA – not available (average excludes corresponding country)
  • DCO and zero survivor rate targets: <2%
  • Staging target: > 70%

Registrations and timeliness
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
2013 341196 113732 300033 32073 9090
2014 342703 114234 300914 32592 9197
2015 345024 115008 303329 32238 9457
2015 (from Previous PI) 340502 113501 299969 31277 9256
No. of 2016 not-finalised cases 679 226 364 315 0
No. of 2016 full cases 343573 114524 303137 30989 9447
Registry creep 1.3% 2.1% 1.1% 3.0% 2.1%
Not-finalised cases 0.2% 0.4% 0.1% 1.0% 0.0%

No. of Cases (current year) and percentage change vs. previous year (persons)
Statistically significant difference in 2016 compared to 2013-2015
No statistical significant difference in 2016 compared to 2013-2015
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
All invasive xnmsc 343,573 (0.2%) -0.4% 303137 (0.6%) 30989 (-4.1%) 9447 (2.2%)
All xnmsc 0-24 3,636 (-4.6%) -8.3% 3243 (-4.5%) 301 (-0.6%) 92 (-19.8%)
All xnmsc 25-59 81,515 (2.1%) 1.1% 71650 (2.5%) 7471 (-1.1%) 2394 (1.9%)
All xnmsc 60-79 183,328 (0.7%) 0.0% 161413 (1.2%) 16871 (-4.2%) 5044 (2.9%)
All xnmsc 80+ 75,094 (-2.9%) -2.6% 66831 (-2.7%) 6346 (-7.1%) 1917 (1.9%)
All registrations 568,075 (1.2%) -0.7% 499061 (1.8%) 51714 (-3.4%) 17300 (-0.4%)
Haematology 30,133 (-1.4%) -1.9% 27038 (-1.2%) 2319 (-4.4%) 776 (-0.1%)
Head and Neck 11,389 (2.8%) -2.2% 9852 (4%) 1230 (-3.8%) 307 (-6.9%)
Lower GI 42,786 (1.1%) -1.6% 37610 (1.7%) 3965 (-2.1%) 1211 (-4.4%)
Upper GI 14,790 (-1.6%) -2.7% 12875 (-0.8%) 1475 (-8.2%) 440 (0.8%)
HPB 17,258 (1.6%) -0.5% 15201 (2.4%) 1574 (-5.5%) 483 (1.7%)
Trachea, Bronchus & Lung 44,701 (0.5%) 0.7% 38381 (1.3%) 4969 (-6.9%) 1351 (7.5%)
Melanoma of skin 15,518 (6.1%) 6.1% 13748 (6%) 1374 (8.4%) 396 (4%)
Breast 52,040 (0.1%) 1.4% 45960 (0.1%) 4634 (-1.8%) 1446 (5.8%)
Cervix 3,015 (-1.3%) -4.8% 2594 (-0.4%) 339 (-6.5%) 82 (-7.5%)
Other Female Genitals 17,782 (2.6%) 0.6% 15680 (3.1%) 1592 (-1.6%) 510 (0.5%)
Prostate 44,762 (-1.6%) -1.2% 40489 (-1.3%) 3108 (-7.1%) 1165 (4.8%)
Kidney 11,711 (-0.9%) -3.4% 10500 (0.1%) 872 (-11.1%) 339 (0.7%)
Bladder 9,519 (-2.6%) 1.5% 8437 (-3.3%) 861 (3.2%) 221 (4.4%)
Brain and CNS 5,251 (0.1%) -5.8% 4702 (1.2%) 417 (-7.2%) 132 (-11.4%)
Thyroid & other endocrine glands 3,745 (2.8%) 5.5% 3353 (3.2%) 289 (-5.6%) 103 (18.8%)
CUP 8,315 (-1.9%) -2.6% 7342 (-1%) 777 (-10.8%) 196 (4.1%)
Other invasive cancer 10,858 (-2.2%) 0.4% 9375 (-2.7%) 1194 (0.5%) 289 (3.3%)
Breast in situ 7,646 (4.4%) 18.1% 6861 (2.6%) 532 (19.6%) 253 (32%)
Cervix in situ 25,315 (-13.9%) -13.4% 21913 (-14.4%) 2482 (-5.2%) 920 (-20.6%)
Other tumours 45,754 (-1%) -2.6% 36754 (0%) 6118 (-6.5%) 2882 (-1.2%)
Other non-melanoma skin cancer 1640 (-4.7%) -21.7% 1442 (-0.9%) 156 (-6.6%) 42 (-57.6%)
Basal cell carcinoma 110777 (7.7%) 3.0% 100030 (8.8%) 8089 (-2.3%) 2658 (2.6%)
Squamous cell carcinoma 33370 (8.5%) 8.2% 28924 (8.8%) 3348 (5.8%) 1098 (10%)

Percentage (%) of death certificate only cases (persons) for 2016
A statistic highlighted in red means that the target was not reached or was not in line with other registries
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
All invasive xnmsc 0.5% 0.4% 0.5% 0.2% 0.4%
All xnmsc 0-24 0.0% 0.0% 0.0% 0.0% 0.0%
All xnmsc 25-59 0.1% 0.1% 0.1% 0.0% 0.0%
All xnmsc 60-79 0.2% 0.2% 0.2% 0.2% 0.2%
All xnmsc 80+ 1.5% 1.2% 1.7% 0.4% 1.5%
All registrations 0.3% 0.2% 0.4% 0.1% 0.3%
Haematology 0.6% 0.4% 0.7% 0.0% 0.5%
Head and Neck 0.2% 0.2% 0.2% 0.0% 0.3%
Lower GI 0.4% 0.3% 0.4% 0.2% 0.3%
Upper GI 0.4% 0.3% 0.5% 0.1% 0.2%
HPB 1.0% 0.6% 1.1% 0.1% 0.8%
Trachea, Bronchus & Lung 0.4% 0.3% 0.4% 0.3% 0.2%
Melanoma of skin 0.1% 0.0% 0.1% 0.0% 0.0%
Breast 0.2% 0.1% 0.2% 0.1% 0.1%
Cervix 0.1% 0.0% 0.1% 0.0% 0.0%
Other Female Genitals 0.5% 0.4% 0.5% 0.2% 0.4%
Prostate 0.4% 0.3% 0.4% 0.0% 0.4%
Kidney 0.4% 0.5% 0.4% 0.3% 0.9%
Bladder 0.6% 0.5% 0.7% 0.0% 0.9%
Brain and CNS 0.6% 0.2% 0.6% 0.0% 0.0%
Thyroid & other endocrine glands 0.2% 0.1% 0.2% 0.0% 0.0%
CUP 3.6% 3.0% 3.8% 1.8% 3.6%
Other invasive cancer 0.9% 0.9% 0.9% 0.3% 1.4%
Breast in situ 0.0% 0.0% 0.0% 0.0% 0.0%
Cervix in situ 0.0% 0.0% 0.0% 0.0% 0.0%
Other tumours 0.5% 0.3% 0.6% 0.1% 0.2%

Percentage (%) of zero survival cases (persons)
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
All invasive xnmsc 1.2% 0.9% 1.3% 0.6% 0.7%
All xnmsc 0-24 0.1% 0.1% 0.2% 0.0% 0.0%
All xnmsc 25-59 0.3% 0.2% 0.4% 0.2% 0.1%
All xnmsc 60-79 0.8% 0.6% 0.9% 0.5% 0.5%
All xnmsc 80+ 3.0% 2.2% 3.2% 1.4% 2.0%
All registrations 0.8% 0.6% 0.8% 0.4% 0.4%
Haematology 1.3% 1.1% 1.3% 0.6% 1.3%
Head and Neck 0.4% 0.4% 0.4% 0.0% 0.7%
Lower GI 1.0% 0.7% 1.1% 0.6% 0.5%
Upper GI 1.4% 0.8% 1.6% 0.4% 0.5%
HPB 2.6% 1.6% 2.8% 0.6% 1.2%
Trachea, Bronchus & Lung 1.8% 1.2% 1.9% 1.1% 0.5%
Melanoma of skin 0.1% 0.0% 0.1% 0.0% 0.0%
Breast 0.3% 0.2% 0.3% 0.2% 0.1%
Cervix 0.3% 0.1% 0.4% 0.0% 0.0%
Other Female Genitals 1.0% 0.8% 1.1% 0.5% 0.8%
Prostate 0.6% 0.4% 0.6% 0.1% 0.6%
Kidney 1.6% 1.3% 1.6% 1.0% 1.2%
Bladder 1.1% 0.8% 1.2% 0.1% 0.9%
Brain and CNS 1.0% 0.5% 1.1% 0.5% 0.0%
Thyroid & other endocrine glands 0.7% 0.5% 0.7% 0.7% 0.0%
CUP 6.8% 5.3% 7.2% 4.1% 4.6%
Other invasive cancer 1.9% 1.7% 2.0% 1.5% 1.7%
Breast in situ 0.0% 0.0% 0.0% 0.0% 0.0%
Cervix in situ 0.0% 0.0% 0.0% 0.0% 0.0%
Other tumours 0.8% 0.5% 0.9% 0.3% 0.2%

Percentage (%) of microscopically verified cases (persons)
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
All invasive xnmsc 85.2% 84.8% 85.3% 83.9% 85.3%
All xnmsc 0-24 94.9% 95.3% 95.0% 93.0% 97.8%
All xnmsc 25-59 96.5% 96.5% 96.5% 96.5% 96.7%
All xnmsc 60-79 88.8% 88.1% 89.1% 87.0% 88.3%
All xnmsc 80+ 63.4% 62.2% 63.8% 60.5% 62.3%
All registrations 90.1% 89.9% 90.2% 89.4% 90.3%
Haematology 88.2% 90.9% 87.5% 95.3% 90.0%
Head and Neck 97.3% 96.0% 97.6% 96.0% 94.5%
Lower GI 88.9% 88.5% 89.0% 88.1% 88.5%
Upper GI 93.1% 92.7% 93.1% 93.0% 92.1%
HPB 52.0% 51.5% 52.6% 45.0% 56.7%
Trachea, Bronchus & Lung 69.5% 67.7% 70.1% 65.0% 67.9%
Melanoma of skin 99.7% 99.7% 99.6% 99.7% 99.8%
Breast 98.7% 99.0% 98.6% 98.9% 99.3%
Cervix 97.8% 98.4% 97.6% 98.8% 98.8%
Other Female Genitals 94.4% 94.5% 94.4% 94.3% 94.9%
Prostate 86.2% 87.2% 86.0% 88.5% 87.0%
Kidney 74.1% 77.2% 73.5% 78.1% 79.9%
Bladder 90.5% 89.4% 91.0% 85.0% 92.3%
Brain and CNS 69.5% 66.9% 69.6% 70.5% 60.6%
Thyroid & other endocrine glands 97.3% 97.9% 97.2% 98.3% 98.1%
CUP 46.7% 43.4% 47.5% 40.4% 42.4%
Other invasive cancer 87.5% 84.9% 88.5% 80.1% 86.2%
Breast in situ 100.0% 100.0% 100.0% 100.0% 100.0%
Cervix in situ 100.0% 100.0% 100.0% 100.0% 100.0%
Other tumours 89.6% 90.5% 89.2% 92.1% 90.2%
Percentage (%) of non-specificity of morphology codes for cases which are microscopically verified
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
All invasive xnmsc 1.2% 1.3% 1.2% 1.2% 1.5%
All xnmsc 0-24 0.4% 0.3% 0.5% 0.4% 0.0%
All xnmsc 25-59 0.8% 0.8% 0.8% 0.8% 0.7%
All xnmsc 60-79 1.1% 1.2% 1.1% 1.0% 1.6%
All xnmsc 80+ 2.4% 2.6% 2.3% 2.7% 2.7%
All registrations 1.0% 1.4% 0.9% 1.0% 2.4%
Haematology 0.8% 0.6% 0.8% 0.4% 0.6%
Head and Neck 1.2% 1.6% 1.2% 1.4% 2.1%
Lower GI 0.6% 0.5% 0.7% 0.4% 0.5%
Upper GI 1.2% 1.8% 1.2% 1.8% 2.5%
HPB 4.8% 4.8% 4.9% 3.5% 5.8%
Trachea, Bronchus & Lung 2.2% 2.3% 2.2% 1.9% 2.7%
Melanoma of skin 0.0% 0.0% 0.0% 0.0% 0.0%
Breast 0.9% 1.1% 0.9% 1.3% 1.2%
Cervix 0.7% 0.6% 0.7% 1.2% 0.0%
Other Female Genitals 0.9% 1.0% 0.9% 1.1% 0.8%
Prostate 0.4% 0.4% 0.4% 0.3% 0.4%
Kidney 0.9% 1.0% 0.8% 2.2% 0.0%
Bladder 0.6% 0.9% 0.6% 0.1% 2.0%
Brain and CNS 0.2% 0.2% 0.2% 0.3% 0.0%
Thyroid & other endocrine glands 1.4% 1.1% 1.4% 1.8% 0.0%
CUP 16.7% 17.6% 16.9% 14.3% 21.7%
Other invasive cancer 0.9% 1.5% 0.8% 1.2% 2.4%
Breast in situ 0.1% 0.0% 0.1% 0.0% 0.0%
Cervix in situ 0.0% 0.0% 0.0% 0.0% 0.0%
Other tumours 2.9% 4.7% 2.5% 2.2% 9.4%

Mortality : Incidence ratios (2016)
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
All invasive xnmsc 0.45 0.47 0.45 0.51 0.44
All xnmsc 0-24 0.13 0.17 0.13 0.13 0.27
All xnmsc 25-59 0.24 0.25 0.23 0.28 0.24
All xnmsc 60-79 0.42 0.45 0.42 0.49 0.45
All xnmsc 80+ 0.78 0.78 0.77 0.87 0.69
All registrations 0.28 0.28 0.28 0.31 0.25
Haematology 0.41 0.41 0.41 0.47 0.36
Head and Neck 0.34 0.38 0.33 0.40 0.43
Lower GI 0.38 0.41 0.38 0.44 0.41
Upper GI 0.80 0.80 0.79 0.83 0.78
HPB 0.86 0.89 0.86 0.90 0.92
Trachea, Bronchus & Lung 0.75 0.79 0.74 0.81 0.82
Melanoma of skin 0.14 0.12 0.14 0.12 0.11
Breast 0.21 0.20 0.21 0.22 0.16
Cervix 0.27 0.26 0.26 0.31 0.20
Other Female Genitals 0.39 0.38 0.38 0.41 0.36
Prostate 0.24 0.23 0.24 0.29 0.17
Kidney 0.35 0.38 0.34 0.47 0.33
Bladder 0.53 0.57 0.52 0.60 0.57
Brain and CNS 0.79 0.83 0.77 0.93 0.77
Thyroid & other endocrine glands 0.14 0.14 0.13 0.18 0.12
CUP 1.05 0.97 1.07 0.99 0.85
Other invasive cancer 0.78 0.69 0.79 0.71 0.57
Breast in situ 0.00 0.00 0.00 0.00 0.01
Cervix in situ 0.00 0.00 0.00 0.00 0.00
Other tumours 0.08 0.06 0.08 0.06 0.04

Completeness of the dataset (%) - demographics and diagnostic details
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
Patient's name 100.0% 100.0% 100.0% 100.0% 100.0%
Patient's address 99.6% 99.8% 99.6% 100.0% 99.9%
Sex 100.0% 100.0% 100.0% 100.0% 100.0%
Ethnicity 88.6% 54.5% 93.2% 70.1% 0.0%
Date of death (where dead) 100.0% 100.0% 100.0% 100.0% 100.0%
Postcode 100.0% 100.0% 100.0% 100.0% 99.9%
Date of birth 100.0% 100.0% 100.0% 100.0% 100.0%
Unique health identifier 99.9% 100.0% 99.9% 100.0% 100.0%
Anniversary (diagnosis) date 99.9% 100.0% 99.9% 100.0% 100.0%
Site of primary growth 97.5% 97.6% 97.5% 97.3% 97.9%
Type of growth 89.4% 88.3% 89.5% 88.9% 86.7%
Behaviour of growth 99.9% 99.9% 100.0% 99.7% 100.0%
Basis of diagnosis 99.5% 99.6% 99.5% 99.9% 99.3%
Diagnosis with hospital 97.2% 91.7% 98.0% 93.5% 83.6%

% of all cancer cases (xnmsc)
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
Treatment 87.1% 79.2% 88.9% 69.5% NA
No Treatment 4.8% 16.3% 2.2% 30.4% NA
Stage I and II patients receiving any treatment (%) 95.1% 90.3% 95.9% 84.7% NA

% of Cases treated with Surgery
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
All invasive xnmsc 48.9% 48.5% 49.5% 42.0% 54.0%
All xnmsc 0-24 52.1% 51.6% 52.1% 53.8% 48.9%
All xnmsc 25-59 66.9% 66.6% 67.4% 61.7% 70.6%
All xnmsc 60-79 48.4% 47.2% 49.1% 39.9% 52.6%
All xnmsc 80+ 30.5% 30.6% 31.0% 23.7% 37.1%
Haematology 6.2% 7.7% 6.1% 6.9% 10.2%
Head and Neck 53.9% 52.2% 54.9% 45.4% 56.4%
Lower GI 68.1% 69.1% 68.5% 60.7% 78.0%
Upper GI 36.2% 37.5% 37.7% 16.7% 58.0%
HPB 31.0% 29.5% 32.6% 10.3% 45.5%
Trachea, Bronchus & Lung 24.8% 22.0% 26.3% 13.2% 26.6%
Melanoma of skin 96.8% 95.1% 96.9% 97.4% 90.9%
Breast 77.8% 79.8% 77.8% 75.9% 85.6%
Cervix 64.3% 63.9% 65.3% 55.8% 70.7%
Other Female Genitals 75.3% 74.7% 75.7% 70.5% 77.8%
Prostate 22.3% 18.6% 23.0% 15.7% 17.0%
Kidney 60.7% 62.9% 61.0% 52.2% 75.5%
Bladder 85.4% 84.9% 86.1% 77.5% 91.0%
Brain and CNS 48.8% 51.0% 48.5% 50.8% 53.8%
Thyroid & other endocrine glands 87.8% 86.0% 88.4% 80.3% 89.3%
CUP 13.2% 12.5% 13.9% 5.1% 18.4%
Other invasive cancer 56.3% 53.7% 57.4% 47.0% 56.7%
Breast in situ 88.7% 88.6% 88.6% 91.5% 85.8%
Cervix in situ 86.8% 66.2% 88.7% 97.6% 12.4%
Other tumours 64.0% 61.9% 63.9% 70.6% 51.1%
Non-Melanoma Skin Cancer 42.2% 61.4% 37.4% 92.1% 54.7%

% of Cases treated with Radiotherapy
UKIACR average (population) UKIACR average (country) England Scotland Northern Ireland Wales Republic of Ireland
All invasive xnmsc 21.2% 20.7% 21.4% 20.0% NA
All xnmsc 0-24 15.3% 13.9% 15.7% 12.0% NA
All xnmsc 25-59 24.4% 24.4% 24.4% 24.3% NA
All xnmsc 60-79 23.7% 22.8% 23.9% 21.7% NA
All xnmsc 80+ 12.2% 11.6% 12.4% 10.8% NA
Haematology 9.9% 9.5% 10.1% 8.8% NA
Head and Neck 58.8% 54.0% 60.2% 47.7% NA
Lower GI 13.4% 13.5% 13.4% 13.5% NA
Upper GI 19.4% 17.2% 20.0% 14.4% NA
HPB 2.5% 2.5% 2.5% 2.4% NA
Trachea, Bronchus & Lung 27.5% 28.3% 27.3% 29.3% NA
Melanoma of skin 0.9% 0.7% 0.9% 0.4% NA
Breast 38.1% 39.0% 37.9% 40.1% NA
Cervix 40.9% 42.2% 40.6% 43.7% NA
Other Female Genitals 15.1% 15.2% 15.1% 15.3% NA
Prostate 20.6% 14.9% 21.5% 8.2% NA
Kidney 5.6% 5.0% 5.8% 4.1% NA
Bladder 17.6% 15.9% 17.9% 13.9% NA
Brain and CNS 47.3% 47.2% 47.3% 47.0% NA
Thyroid & other endocrine glands 31.4% 28.2% 32.1% 24.2% NA
CUP 12.1% 11.5% 12.3% 10.7% NA
Other invasive cancer 16.6% 15.3% 17.0% 13.6% NA
Breast in situ 33.2% 37.2% 32.5% 41.9% NA
Cervix in situ 0.0% 0.0% 0.0% 0.0% NA
Other tumours 1.1% 0.8% 1.3% 0.2% NA
Non-Melanoma Skin Cancer 1.9% 1.2% 2.0% 0.4% NA

% of Cases treated with Teletherapy
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
All invasive xnmsc 20.2% 20.2% 20.2% NA NA
All xnmsc 0-24 12.3% 12.3% 12.3% NA NA
All xnmsc 25-59 22.5% 22.5% 22.5% NA NA
All xnmsc 60-79 22.6% 22.6% 22.6% NA NA
All xnmsc 80+ 12.0% 12.0% 12.0% NA NA
Haematology 9.8% 9.8% 9.8% NA NA
Head and Neck 59.5% 59.5% 59.5% NA NA
Lower GI 13.1% 13.1% 13.1% NA NA
Upper GI 19.2% 19.2% 19.2% NA NA
HPB 2.1% 2.1% 2.1% NA NA
Trachea, Bronchus & Lung 26.9% 26.9% 26.9% NA NA
Melanoma of skin 0.9% 0.9% 0.9% NA NA
Breast 37.7% 37.7% 37.7% NA NA
Prostate 39.1% 39.1% 39.1% NA NA
Cervix 9.7% 9.7% 9.7% NA NA
Other Female Genitals 19.6% 19.6% 19.6% NA NA
Kidney 5.6% 5.6% 5.6% NA NA
Bladder 17.7% 17.7% 17.7% NA NA
Brain and CNS 46.5% 46.5% 46.5% NA NA
Thyroid & other endocrine glands 7.5% 7.5% 7.5% NA NA
CUP 12.0% 12.0% 12.0% NA NA
Other invasive cancer 13.2% 13.2% 13.2% NA NA
Breast in situ 32.5% 32.5% 32.5% NA NA
Cervix in situ 0.0% 0.0% 0.0% NA NA
Other tumours 1.1% 1.1% 1.1% NA NA
Non-Melanoma Skin Cancer 2.0% 2.0% 2.0% NA NA

% of Cases treated with Chemotherapy
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
All invasive xnmsc 26.6% 26.7% 26.6% 25.5% 28.0%
All xnmsc 0-24 59.2% 60.1% 59.4% 54.5% 66.3%
All xnmsc 25-59 40.0% 41.2% 39.8% 41.3% 42.5%
All xnmsc 60-79 27.3% 26.7% 27.6% 25.3% 27.3%
All xnmsc 80+ 8.4% 8.2% 8.6% 6.1% 9.9%
Haematology 53.0% 55.8% 52.6% 55.0% 59.9%
Head and Neck 30.0% 25.2% 31.1% 23.6% 20.8%
Lower GI 32.4% 31.0% 32.6% 31.2% 29.3%
Upper GI 39.9% 40.9% 40.1% 37.0% 45.7%
HPB 23.6% 23.9% 24.0% 17.6% 30.0%
Trachea, Bronchus & Lung 27.1% 24.3% 27.9% 21.5% 23.5%
Melanoma of skin 1.4% 2.1% 1.4% 0.1% 4.8%
Breast 32.4% 34.5% 32.2% 31.5% 39.9%
Cervix 37.5% 41.1% 36.7% 41.6% 45.1%
Other Female Genitals 30.1% 32.4% 29.6% 34.7% 32.9%
Prostate 6.2% 6.7% 6.0% 8.5% 5.6%
Kidney 8.1% 6.8% 8.5% 2.5% 9.4%
Bladder 29.3% 26.4% 29.7% 27.9% 21.7%
Brain and CNS 30.2% 31.3% 30.0% 31.4% 32.6%
Thyroid & other endocrine glands 4.5% 3.2% 4.7% 3.1% 1.9%
CUP 11.8% 10.5% 12.1% 9.1% 10.2%
Other invasive cancer 29.3% 28.5% 29.6% 26.9% 29.1%
Breast in situ 1.8% 1.6% 1.9% 0.9% 2.0%
Cervix in situ 0.0% 0.0% 0.0% 0.0% 0.1%
Other tumours 12.6% 11.3% 13.0% 12.6% 8.3%
Non-Melanoma Skin Cancer 0.2% 0.5% 0.1% 0.7% 0.8%

% of Cases for other treatments
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
% of Cases treated with Hormone Therapy
All invasive xnmsc 12.9% 15.4% 12.4% 15.6% 18.1%
Breast 41.2% 55.0% 38.3% 63.5% 63.1%
Prostate 48.0% 53.0% 47.4% 52.8% 58.7%
% of Cases treated with Brachytherapy
All invasive xnmsc 1.3% 1.0% 1.3% NA 0.6%
Breast 0.1% 0.1% 0.1% NA 0.1%
Prostate 2.6% 3.4% 2.6% NA 4.1%
% of Cases treated with Watch & Wait/Active Monitoring
All invasive xnmsc 8.4% 8.2% 8.4% NA 7.9%
Prostate 25.5% 22.5% 25.7% NA 19.2%
% of Cases treated with Palliative Care
All invasive xnmsc 9.3% 8.7% 9.3% NA 8.1%

Specific cohorts where treatment completeness data is expected (%)
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
% of children and young adults (0-24 group) with cancer & underwent any treatment 95.1% 95.0% 95.3% 93.0% 96.7%
% of men under 60 with prostate cancer & received hormone treatment 22.4% 29.7% 21.3% 29.6% 38.1%
% of men under 60 with cancer (C00-C97 exc. C44) & received hormone treatment 3.9% 5.3% 3.7% 4.7% 7.5%
% of women under 60 with breast cancer & received hormone treatment 27.5% 42.5% 24.3% 49.8% 53.5%
% of all haematological cancer patients who received any treatment 82.2% 73.0% 84.0% 62.0%

Quality of treatment data
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
Surgery (denominator - all tumours known to be treated with surgery, first recorded surgery for that tumour):
Date of surgery known 100.0% 100.0% 100.0% 100.0% 100.0%
Trust / hospital of surgery known 99.8% 99.9% 99.8% 100.0% 100.0%
Type of surgery known (OPCS4 code) 99.8% 96.6% 100.0% NA 93.1%
Teletherapy (denominator - all tumours known to be treated with teletherapy , first recorded teletherapy treatment for that tumour):
Date of teletherapy known 100.0% 100.0% 100.0% NA NA
Trust / hospital of teletherapy known 100.0% 100.0% 100.0% NA NA
Fractions and dose known 94.1% 94.1% 94.1% NA NA
Chemotherapy (denominator - all tumours known to be treated with chemotherapy, first recorded chemotherapy treatment for that tumour):
Date of chemotherapy known 99.8% 99.9% 99.8% 100.0% 100.0%
Trust / hospital of chemotherapy known 99.9% 100.0% 99.9% 100.0% 100.0%
Drug name or regimen known 40.9% 13.6% 0.0% 0.0% 40.9%
Radiotherapy (denominator - all tumours known to be treated with radiotherapy, take the first recorded radiotherapy event for that tumour):
Date of radiotherapy known 100.0% 100.0% 100.0% 100.0% NA
Trust / hospital of radiotherapy known 100.0% 100.0% 100.0% 100.0% NA

Breast cancer screening completeness (%)
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
Breast cancer - % screen detected for ages 50-64 (data 2016) 41.7% 45.5% 40.8% 48.1% 47.7%
Breast cancer - % screen detected for ages 50-64 (last year, 2015) 45.1% 48.1% 44.3% 51.4% 48.4%
Breast cancer - % with full screening history for ages 50-64 (data 2016) 78.9% 88.3% 76.6% 100.0% NA
Breast cancer - % with full screening history for ages 50-64 (last year, 2015) 87.2% 92.9% 85.9% 99.9% NA

Cervical cancer screening completeness (%)
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
Cervical cancer - % screen detected for ages 25-60 (data 2016) 14.7% 30.0% 9.9% 50.2% NA
Cervical cancer - % screen detected for ages 25-60 (last year, 2015) 32.0% 37.7% 30.0% 45.3% NA
Cervical cancer - % with full screening history for ages 25-60 (data 2016) 55.2% 55.1% 10.2% 100.0% NA
Cervical cancer - % with full screening history for ages 25-60 (last year, 2015) 21.0% 74.3% 48.6% 100.0% NA

Bowel cancer screening completeness (%)
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
Bowel cancer - % screen detected for ages 60-69 (data 2016) 2.9% 14.4% 0.0% 28.7% NA
Bowel cancer - % screen detected for ages 60-69 (last year, 2015) 24.9% 25.9% 24.6% 27.1% NA
Bowel cancer - % with full screening history for ages 60-69 (data 2016) 9.9% 49.8% 0.0% 99.7% NA
Bowel cancer - % with full screening history for ages 60-69 (last year, 2015) 98.4% 99.0% 98.3% 99.7% NA

Completeness of the dataset (%) - stage complete by cancer site groups summary (persons)
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
All invasive xnmsc 80.6% 77.9% 81.9% 67.2% 84.7%
Haematology 67.0% 50.6% 71.9% 0.0% 79.9%
Head and Neck 88.6% 86.6% 89.9% 76.8% 93.2%
Lower GI 88.8% 84.8% 90.4% 73.6% 90.5%
Upper GI 80.6% 72.6% 82.5% 67.8% 67.5%
HPB 71.0% 72.6% 70.7% 72.9% 74.3%
Trachea, Bronchus & Lung 93.2% 93.2% 93.4% 91.7% 94.6%
Melanoma of skin 89.8% 77.2% 94.6% 38.8% 98.2%
Breast 92.7% 91.4% 93.4% 84.8% 96.1%
Cervix 92.7% 95.6% 92.1% 95.9% 98.8%
Other Female Genitals 86.7% 86.1% 87.5% 76.0% 94.8%
Prostate 90.0% 89.4% 90.3% 84.3% 93.6%
Bladder 84.9% 79.3% 87.4% 59.2% 91.4%
Kidney 86.2% 85.4% 87.1% 74.1% 95.0%
Thyroid and other endocrine glands 72.1% 82.6% 70.7% 78.9% 98.1%
Other invasive cancer 62.5% 51.6% 66.3% 25.4% 63.1%
Non-Melanoma Skin Cancer 4.2% 5.3% 4.3% 0.0% 11.7%

Completeness of the dataset (%) - grade complete by cancer site groups summary (persons)
Country average (population) Country average (country) England Scotland Northern Ireland Wales Republic of Ireland
All invasive xnmsc 60.2% 61.1% 60.2% 58.6% 64.4%
All xnmsc 0-24 32.6% 46.6% 30.8% 41.5% 67.4%
All xnmsc 25-59 67.6% 68.6% 67.4% 67.9% 70.4%
All xnmsc 60-79 64.6% 65.3% 64.7% 62.3% 69.0%
All xnmsc 80+ 42.5% 42.1% 42.9% 38.5% 44.9%
All registrations 45.0% 42.9% 45.3% 44.0% 39.4%
Haematology 16.3% 40.3% 13.2% 33.1% 74.5%
Head and Neck 82.7% 82.9% 82.6% 83.7% 82.4%
Lower GI 80.7% 79.3% 80.9% 80.5% 76.6%
Upper GI 79.1% 75.5% 79.7% 77.5% 69.3%
HPB 28.0% 26.0% 28.5% 22.9% 26.7%
Trachea, Bronchus & Lung 28.5% 27.6% 28.8% 26.0% 28.1%
Melanoma of skin 0.8% 0.4% 0.9% 0.2% 0.0%
Breast 95.7% 93.5% 96.4% 89.9% 94.2%
Cervix 81.5% 78.8% 81.9% 80.2% 74.4%
Other Female Genitals 76.7% 77.6% 76.5% 77.2% 79.2%
Prostate 83.6% 85.3% 83.3% 86.6% 86.1%
Kidney 61.1% 63.5% 61.0% 58.0% 71.4%
Bladder 86.2% 85.4% 86.8% 79.4% 90.0%
Brain and CNS 71.0% 71.7% 71.1% 68.1% 75.8%
Thyroid and other endocrine glands 20.3% 12.2% 21.5% 12.1% 2.9%
CUP 22.0% 19.6% 22.5% 18.4% 17.9%
Other invasive cancer 31.6% 32.6% 31.6% 30.2% 36.0%
Other tumours 37.7% 23.8% 43.2% 16.5% 11.7%
Non-Melanoma Skin Cancer 16.2% 17.7% 15.3% 27.5% 10.1%